TNF and acute kidney injury: Both in vitro and in vivo, cisplatin was shown to activate p38-MAPK [67]. In vivo, SKF-86002, a p38-MAPK inhibitor, significantly decreased TNF-alpha levels and protected against cisplatin-induced AKI.